[
  {
    "ts": null,
    "headline": "Hartford Core Equity Fund Q2 2025 Commentary",
    "summary": "Hartford Core Equity (I share) underperformed the S&P 500 Index during the quarter. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=dd26b9300223d39082b52e239e1f9e3dd31d3237afb0433c8072528e1ef7d45a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755646500,
      "headline": "Hartford Core Equity Fund Q2 2025 Commentary",
      "id": 136433822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1278896005/image_1278896005.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hartford Core Equity (I share) underperformed the S&P 500 Index during the quarter. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=dd26b9300223d39082b52e239e1f9e3dd31d3237afb0433c8072528e1ef7d45a"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics stock plunges: Weight-loss pill trial disappoints",
    "summary": "Viking Therapeutics (VKTX) shares plunge after revealing a high dropout rate in the phase 2 trial for its weight-loss pill.  Yahoo Finance Senior Health Reporter Anjalee Khemlani outlines the latest and what to watch. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=a431b73639792fa86f26aa79937aa5635a435ce5118bd2dcb005e0ca1157121c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755633369,
      "headline": "Viking Therapeutics stock plunges: Weight-loss pill trial disappoints",
      "id": 136431710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics (VKTX) shares plunge after revealing a high dropout rate in the phase 2 trial for its weight-loss pill.  Yahoo Finance Senior Health Reporter Anjalee Khemlani outlines the latest and what to watch. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=a431b73639792fa86f26aa79937aa5635a435ce5118bd2dcb005e0ca1157121c"
    }
  },
  {
    "ts": null,
    "headline": "Viking’s stock plummets on obesity pill trial results",
    "summary": "VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.",
    "url": "https://finnhub.io/api/news?id=69984b00a914d9bdd19b8702e99c278f778c5e717123ece1e9dce6a342326605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755626587,
      "headline": "Viking’s stock plummets on obesity pill trial results",
      "id": 136431711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.",
      "url": "https://finnhub.io/api/news?id=69984b00a914d9bdd19b8702e99c278f778c5e717123ece1e9dce6a342326605"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell",
    "summary": "Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this raises doubts about VKTX and its future.",
    "url": "https://finnhub.io/api/news?id=1d3b1820dae40ec15e092f210905d072fd5ba942232f2d92e8569d698d10c552",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755626139,
      "headline": "Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell",
      "id": 136432566,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288653784/image_1288653784.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this raises doubts about VKTX and its future.",
      "url": "https://finnhub.io/api/news?id=1d3b1820dae40ec15e092f210905d072fd5ba942232f2d92e8569d698d10c552"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone",
    "summary": "Shares of Viking Therapeutics (VKTX) tumbled intraday Tuesday after the company released trial data",
    "url": "https://finnhub.io/api/news?id=309106de6e2e77fe1966fd0d333a42f0a11944d01e74e427e1145068f98ca2d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755623392,
      "headline": "Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone",
      "id": 136431174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Viking Therapeutics (VKTX) tumbled intraday Tuesday after the company released trial data",
      "url": "https://finnhub.io/api/news?id=309106de6e2e77fe1966fd0d333a42f0a11944d01e74e427e1145068f98ca2d9"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill",
    "summary": "Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill",
    "url": "https://finnhub.io/api/news?id=05dcd287ebf18014f77c16c3b2fc64a6623d09bf6754129081efecff27e3fb75",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755619507,
      "headline": "Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill",
      "id": 136439921,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill",
      "url": "https://finnhub.io/api/news?id=05dcd287ebf18014f77c16c3b2fc64a6623d09bf6754129081efecff27e3fb75"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Popped Today",
    "summary": "For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.",
    "url": "https://finnhub.io/api/news?id=70e1d08e859d503c3153aaaf2ca55d333d6c0e482bd9c93da05383bf9d8cee1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755617041,
      "headline": "Why Novo Nordisk Stock Popped Today",
      "id": 136430044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.",
      "url": "https://finnhub.io/api/news?id=70e1d08e859d503c3153aaaf2ca55d333d6c0e482bd9c93da05383bf9d8cee1e"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate",
    "summary": "Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a high patient dropout rate.",
    "url": "https://finnhub.io/api/news?id=edb7485025eec5873aeffea2e12a37cf39dbf4a5a3ab7c65a54e06794e1ba776",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755615437,
      "headline": "Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate",
      "id": 136430045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a high patient dropout rate.",
      "url": "https://finnhub.io/api/news?id=edb7485025eec5873aeffea2e12a37cf39dbf4a5a3ab7c65a54e06794e1ba776"
    }
  },
  {
    "ts": null,
    "headline": "This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.",
    "summary": "Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=46fdc9825ca7e9511c9964372ebc087317a7456ac6a09b9699ab779bbdae8d83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755613020,
      "headline": "This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.",
      "id": 136430046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=46fdc9825ca7e9511c9964372ebc087317a7456ac6a09b9699ab779bbdae8d83"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill",
    "summary": "Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=065fcf46e896fb9d636ec9a1f6af73f29d63e089246eab21b07293bbc904d89a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608435,
      "headline": "Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill",
      "id": 136418426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=065fcf46e896fb9d636ec9a1f6af73f29d63e089246eab21b07293bbc904d89a"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Slumps as Weight-Loss Pill Underwhelms",
    "summary": "The pill, known as VK2735, helped patients lose up to 12.2% of their body weight, Viking said in a statement.  “The thing to consider here is that patients discontinued at such a high rate over 13 weeks,” Mizuho’s Jared Holz said in a note.  Viking’s stock fell more than 40% at the start of regular trading in New York Tuesday, the most since April 2016.",
    "url": "https://finnhub.io/api/news?id=76efe8833512f14c9657dfd33a170153b6a95c6edf11f20e5fd77477d2772304",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755610523,
      "headline": "Viking Therapeutics Slumps as Weight-Loss Pill Underwhelms",
      "id": 136430049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pill, known as VK2735, helped patients lose up to 12.2% of their body weight, Viking said in a statement.  “The thing to consider here is that patients discontinued at such a high rate over 13 weeks,” Mizuho’s Jared Holz said in a note.  Viking’s stock fell more than 40% at the start of regular trading in New York Tuesday, the most since April 2016.",
      "url": "https://finnhub.io/api/news?id=76efe8833512f14c9657dfd33a170153b6a95c6edf11f20e5fd77477d2772304"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, Eli Lilly rise after Viking obesity trial data",
    "summary": "Investing.com -- Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.",
    "url": "https://finnhub.io/api/news?id=2ff45cf84442b3c2be25a89619999ac6c46140389a35b519838bfa5ee0f1713e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608370,
      "headline": "Novo Nordisk, Eli Lilly rise after Viking obesity trial data",
      "id": 136418427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.",
      "url": "https://finnhub.io/api/news?id=2ff45cf84442b3c2be25a89619999ac6c46140389a35b519838bfa5ee0f1713e"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics stock falls 37% on high dropout rate in obesity trial",
    "summary": "Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages.",
    "url": "https://finnhub.io/api/news?id=eb31e86313f93cb760d04429314f9c6e344e72a1e7dceb64960e84acc4d7c773",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755606569,
      "headline": "Viking Therapeutics stock falls 37% on high dropout rate in obesity trial",
      "id": 136417907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages.",
      "url": "https://finnhub.io/api/news?id=eb31e86313f93cb760d04429314f9c6e344e72a1e7dceb64960e84acc4d7c773"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success",
    "summary": "Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock dip a buy. Click for my VKTX update.",
    "url": "https://finnhub.io/api/news?id=e7f9aff092c82d26047adb7bb9259ee566e8cea9b216d79dd33ce1ab68f2ef65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755604984,
      "headline": "Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success",
      "id": 136425069,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2020900595/image_2020900595.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock dip a buy. Click for my VKTX update.",
      "url": "https://finnhub.io/api/news?id=e7f9aff092c82d26047adb7bb9259ee566e8cea9b216d79dd33ce1ab68f2ef65"
    }
  },
  {
    "ts": null,
    "headline": "2 Outstanding ‘Strong Buy’ Stocks to Grab in August",
    "summary": "These two stocks offer a rare combination of income and growth.",
    "url": "https://finnhub.io/api/news?id=668e3925a37eaf649f623c79fc67ac0a2c258bacc254db6cc5f467df826327f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755603002,
      "headline": "2 Outstanding ‘Strong Buy’ Stocks to Grab in August",
      "id": 136430052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These two stocks offer a rare combination of income and growth.",
      "url": "https://finnhub.io/api/news?id=668e3925a37eaf649f623c79fc67ac0a2c258bacc254db6cc5f467df826327f9"
    }
  },
  {
    "ts": null,
    "headline": "PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds",
    "summary": "The FDA said data for PTC's drug did not prove \"substantial evidence of efficacy.\" Elsewhere, the FDA delayed its decision on a Regenxbio gene therapy and Skyhawk Therapeutics struck a deal.",
    "url": "https://finnhub.io/api/news?id=b7b17258c892ab861ac4074c885453952f50939abb7ef4e9a05d070b0a0c9d67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755601980,
      "headline": "PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds",
      "id": 136430054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The FDA said data for PTC's drug did not prove \"substantial evidence of efficacy.\" Elsewhere, the FDA delayed its decision on a Regenxbio gene therapy and Skyhawk Therapeutics struck a deal.",
      "url": "https://finnhub.io/api/news?id=b7b17258c892ab861ac4074c885453952f50939abb7ef4e9a05d070b0a0c9d67"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval",
    "summary": "Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.",
    "url": "https://finnhub.io/api/news?id=b76339b347f0079dd63a6327b38ab882891f0550effc31dfb7987d58acc65cbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755599400,
      "headline": "Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval",
      "id": 136430055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.",
      "url": "https://finnhub.io/api/news?id=b76339b347f0079dd63a6327b38ab882891f0550effc31dfb7987d58acc65cbb"
    }
  },
  {
    "ts": null,
    "headline": "Bank On Healthcare And An Aging Population With 14% Yield: HQH",
    "summary": "Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key sector.",
    "url": "https://finnhub.io/api/news?id=51e0b31c470fe3a32598b7340dd31af509a06ea732c62173163dd76df69c1d09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755588900,
      "headline": "Bank On Healthcare And An Aging Population With 14% Yield: HQH",
      "id": 136417379,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195105991/image_2195105991.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key sector.",
      "url": "https://finnhub.io/api/news?id=51e0b31c470fe3a32598b7340dd31af509a06ea732c62173163dd76df69c1d09"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Large Cap Growth Fund Q2 2025 Commentary",
    "summary": "For 2Q25, Macquarie Large Cap Growth Fund Institutional Class shares posted absolute positive returns but underperformed the Fundâs benchmark, the Russell 1000 Growth Index.",
    "url": "https://finnhub.io/api/news?id=d56b75487b8b434fd73ca54531dce3c1ee0c218d38002fdae2b770fdccc54d03",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755588300,
      "headline": "Macquarie Large Cap Growth Fund Q2 2025 Commentary",
      "id": 136417240,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1881807987/image_1881807987.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For 2Q25, Macquarie Large Cap Growth Fund Institutional Class shares posted absolute positive returns but underperformed the Fundâs benchmark, the Russell 1000 Growth Index.",
      "url": "https://finnhub.io/api/news?id=d56b75487b8b434fd73ca54531dce3c1ee0c218d38002fdae2b770fdccc54d03"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Large Cap Growth Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports Q2 results for its Large Cap Growth Fund, highlighting AI-driven gains and sector rotation. Explore key holdings and outlook.",
    "url": "https://finnhub.io/api/news?id=3dcf0ebf33c99392f088a380d54e9ce8ab86d25e7c53d6abcf67aa2fd87c0d95",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755576600,
      "headline": "Columbia Large Cap Growth Fund Q2 2025 Commentary",
      "id": 136416076,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209036461/image_2209036461.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports Q2 results for its Large Cap Growth Fund, highlighting AI-driven gains and sector rotation. Explore key holdings and outlook.\n",
      "url": "https://finnhub.io/api/news?id=3dcf0ebf33c99392f088a380d54e9ce8ab86d25e7c53d6abcf67aa2fd87c0d95"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Partners with Superluminal for AI Drug Discovery",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 14, Reuters reported that Eli Lilly and Company (NYSE:LLY) has entered into a deal worth $1.3 billion with Superluminal Medicines, a privately held company. The aim of this deal is to use AI to […]",
    "url": "https://finnhub.io/api/news?id=450576d5cd1b93ffad65e2ba639a62c132445baf18fe8bee1871bb6ae0a84f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755573295,
      "headline": "Eli Lilly (LLY) Partners with Superluminal for AI Drug Discovery",
      "id": 136416848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 14, Reuters reported that Eli Lilly and Company (NYSE:LLY) has entered into a deal worth $1.3 billion with Superluminal Medicines, a privately held company. The aim of this deal is to use AI to […]",
      "url": "https://finnhub.io/api/news?id=450576d5cd1b93ffad65e2ba639a62c132445baf18fe8bee1871bb6ae0a84f7f"
    }
  }
]